Media Contact: Alexandra Curbelo
Wragg & Casas Public Relations
1221 Brickell Avenue, Suite 730
Miami, Fl. 33131
305-372-1234 ex.124
Email: acurbelo@wraggcasas.com

For Immediate Release

BIOHEART ANNOUNCES CONTRACT WITH AFRICAN-MIDDLE EAST MEDICAL (AFRIMID) TO BEGIN DISTRIBUTING STEM CELL PRODUCTS IN UGANDA

Sunrise, FL – October 16, 2013 - Bioheart, Inc. (BHRT.OB), a biotechnology company focused on the discovery, development and commercialization of autologous cell therapies, announced today it has signed a contract with African-Middle East Medical (AFRIMID) to implement Bioheart therapies for the more than 36 million patients in Uganda. Bioheart will begin distributing MyoCell™ (muscle derived stem cells) and AdipoCell™ (adipose derived stem cells) for a variety of indications in Uganda.

"We are looking forward to bringing our therapies to Uganda and expanding the list of indications for our products," said Kristin Comella, Bioheart's Chief Science Officer. "There are many patients who can benefit from regenerative medicine and we are hopeful that these therapies can offer new hope to patients suffering from debilitating diseases."

MyoCell™ is currently under investigation in an FDA Phase II/III US trial for congestive heart failure. AdipoCell™ is currently utilized at Bioheart Centers of Excellence throughout the world for indications including arthritis, limb ischemia, diabetes, heart disease, and more.

-MORE-

"We have many patients with degenerative diseases that could benefit from cellular therapies," said Dr. Robert Basaza, Assistant Commissioner of Health Services of the Uganda Ministry of Health. "We are excited to implement the good scientific work of Bioheart into our clinics in Uganda. It is our intention to make these therapies the standard of care for our country."

About Bioheart, Inc.

Bioheart is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. Bioheart's goals are to cause damaged tissue to be regenerated, when possible, and to improve a patient's quality of life and reduce health care costs and hospitalizations.

Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. Its leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. For more information on Bioheart, visit www.bioheartinc.com, or visit us on Facebook: Bioheart and Twitter @BioheartInc.

###